{"id":949274,"date":"2026-04-06T18:20:37","date_gmt":"2026-04-06T22:20:37","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-receives-european-patent-allowance-for-licensed-novel-ptsd-prevention-therapy\/"},"modified":"2026-04-06T18:20:37","modified_gmt":"2026-04-06T22:20:37","slug":"silo-pharma-receives-european-patent-allowance-for-licensed-novel-ptsd-prevention-therapy","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-receives-european-patent-allowance-for-licensed-novel-ptsd-prevention-therapy\/","title":{"rendered":"Silo Pharma Receives European Patent Allowance for Licensed Novel PTSD Prevention Therapy"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"center\">\n        <i>EPO Greenlights Claims Covering Preventative use of therapy targeting 5-HT4 Pathway and Expands Silo Pharma IP Portfolio<\/i>\n      <\/p>\n<p align=\"justify\">SARASOTA, FL, April  06, 2026  (GLOBE NEWSWIRE) &#8212;  Silo Pharma, Inc. (Nasdaq: SILO) (\u201cSilo\u201d or the \u201cCompany\u201d), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced that the European Patent Office (EPO) has issued a Rule 71(3) communication indicating its intent to grant a patent for an European patent application titled\u00a0<i>\u201cProphylactic Efficacy of Serotonin 4 Receptor Agonists Against Stress\u201d<\/i> (European Patent Application No. 20786878.7) that the Company has an exclusive license from Columbia University.<\/p>\n<p align=\"justify\">The allowed claims cover methods of preventing stress-induced fear and depressive-like behavior and associated affective disorders using selected serotonin 4 (5-HT4) receptor agonists \u2014 a differentiated approach targeting pathways associated with stress resilience rather than just symptom management.<\/p>\n<p align=\"justify\">\u201cThis is a high-value milestone that strengthens our global intellectual property position and underscores the potential of our 5-HT4 program,\u201d said Eric Weisblum, CEO of Silo Pharma. \u201cWe believe this approach represents a compelling shift toward proactive treatment of stress-related disorders, which remain a massive and underserved market.\u201d<\/p>\n<p align=\"justify\">The patent, once granted, is expected to protect major European markets, further enhancing Silo\u2019s strategic positioning as it advances its pipeline. The Company is evaluating Unitary Patent protection and key national validations to maximize geographic coverage and long-term value.<\/p>\n<p align=\"justify\">With growing global focus on mental health and stress-related conditions, Silo Pharma continues to build a portfolio targeting next-generation CNS therapeutics with differentiated mechanisms of action.<\/p>\n<p>\n        <b>About Silo Pharma, Inc.<\/b>\n      <\/p>\n<p align=\"justify\">Silo Pharma is a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company. Its therapeutic focus is on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The Company\u2019s portfolio includes innovative programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer\u2019s disease. Silo\u2019s research is conducted in collaboration with leading universities and laboratories. <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=XFNmhtneYTeK6KUcqJauTaUYsg0GVtrbqns55fZrUXU69Np4ceQBeYpZjDDMDD_2LUjI3TLq215GoZ7gImpqeuBGxky1C94Nv6NHdqEuy--jPK9-ETIKelbMIvr3UUdWUTB4KfQeCzlryS4151fZ7QrrJCujaJ2HlJoDNx49h4qrNZ-ucXEk-W8vVwdK0kWGa2ybGuc2yua8ZLDpbPhwGJ0B-k04KEjT4PRBX2eM0uc8bH3hfyTZGf360aVOttAGyGp4ZYSciRMKBXQGRTLYBQChFCMDWYyKLGWu7Bn9JfUubWCf_slOp5s_VjXSo95gxh4wC85s-akeOLKJramrvuwFVggF0qGcdyxrf-ii5KnxUzYnP1Po2Z_2Mt-wKYw_R3P2FoTJN_P30Qw2fzm0Mqg2i14wCNCQhCHjwKEFyg0=\" rel=\"nofollow\" target=\"_blank\"><u>silopharma.com<\/u><\/a><\/p>\n<p>\n        <b>Forward Looking Statements<\/b>\n      <\/p>\n<p align=\"justify\">This news release contains \u201cforward-looking statements\u201d within the meaning of the \u201csafe harbor\u201d provisions of the Private Securities Litigation Reform Act of 1995. These statements are identified using words \u201ccould\u201d, \u201cbelieve\u201d, \u201canticipate\u201d, \u201cintend\u201d, \u201cestimate\u201d, \u201cexpect\u201d, \u201cmay\u201d, \u201ccontinue\u201d, \u201cpredict\u201d, \u201cpotential\u201d, and similar expressions that are intended to identify forward-looking statements. Such statements involve known and unknown risks, uncertainties, and other factors that could cause the actual results of the Company to differ materially from the results expressed or implied by such statements, including statements about the intended use of proceeds from the offering, changes to anticipated sources of revenues, future economic and competitive conditions, difficulties in developing the Company\u2019s technology platforms, retaining and expanding the Company\u2019s customer base, fluctuations in consumer spending on the Company\u2019s products and other factors. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company disclaims any obligations to publicly update or release any revisions to the forward-looking information contained in this press release, whether as a result of new information, future events, or otherwise, after the date of this press release or to reflect the occurrence of unanticipated events except as required by law.<\/p>\n<p align=\"justify\">\n        <b>Contact<\/b><br \/>\n        <br \/>(800) 705-0120<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=C1G4Ppl7kIHkzvptwISxWJbFXCLqQ1FTeYPYSm1W5bAEYsuzuUKhavNWcKFxhmZqVFDRz6FZukUy7JGQpbfNUEvKH8Isq9Vt85YghDFG-OlWc0G3f5WwE3QbJXAJz4Ap\" rel=\"nofollow\" target=\"_blank\">investors@silopharma.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4NDc0OSM3NTIxNTM3IzUwMDA2OTMzOQ==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/NTc2ODQ5NDQtYjZiNi00MGIzLTk5ZWItZTg0OGU3OGM2N2VkLTUwMDA2OTMzOS0yMDI2LTA0LTA2LWVu\/tiny\/Silo-Pharma-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>EPO Greenlights Claims Covering Preventative use of therapy targeting 5-HT4 Pathway and Expands Silo Pharma IP Portfolio SARASOTA, FL, April 06, 2026 (GLOBE NEWSWIRE) &#8212; Silo Pharma, Inc. (Nasdaq: SILO) (\u201cSilo\u201d or the \u201cCompany\u201d), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced that the European Patent Office (EPO) has issued a Rule 71(3) communication indicating its intent to grant a patent for an European patent application titled\u00a0\u201cProphylactic Efficacy of Serotonin 4 Receptor Agonists Against Stress\u201d (European Patent Application No. 20786878.7) that the Company has an exclusive license from Columbia University. The allowed claims cover methods of preventing stress-induced fear and depressive-like behavior and associated affective disorders &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-receives-european-patent-allowance-for-licensed-novel-ptsd-prevention-therapy\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Silo Pharma Receives European Patent Allowance for Licensed Novel PTSD Prevention Therapy&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-949274","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Silo Pharma Receives European Patent Allowance for Licensed Novel PTSD Prevention Therapy - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-receives-european-patent-allowance-for-licensed-novel-ptsd-prevention-therapy\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Silo Pharma Receives European Patent Allowance for Licensed Novel PTSD Prevention Therapy - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"EPO Greenlights Claims Covering Preventative use of therapy targeting 5-HT4 Pathway and Expands Silo Pharma IP Portfolio SARASOTA, FL, April 06, 2026 (GLOBE NEWSWIRE) &#8212; Silo Pharma, Inc. (Nasdaq: SILO) (\u201cSilo\u201d or the \u201cCompany\u201d), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced that the European Patent Office (EPO) has issued a Rule 71(3) communication indicating its intent to grant a patent for an European patent application titled\u00a0\u201cProphylactic Efficacy of Serotonin 4 Receptor Agonists Against Stress\u201d (European Patent Application No. 20786878.7) that the Company has an exclusive license from Columbia University. The allowed claims cover methods of preventing stress-induced fear and depressive-like behavior and associated affective disorders &hellip; Continue reading &quot;Silo Pharma Receives European Patent Allowance for Licensed Novel PTSD Prevention Therapy&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-receives-european-patent-allowance-for-licensed-novel-ptsd-prevention-therapy\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-06T22:20:37+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4NDc0OSM3NTIxNTM3IzUwMDA2OTMzOQ==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-receives-european-patent-allowance-for-licensed-novel-ptsd-prevention-therapy\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-receives-european-patent-allowance-for-licensed-novel-ptsd-prevention-therapy\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Silo Pharma Receives European Patent Allowance for Licensed Novel PTSD Prevention Therapy\",\"datePublished\":\"2026-04-06T22:20:37+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-receives-european-patent-allowance-for-licensed-novel-ptsd-prevention-therapy\\\/\"},\"wordCount\":554,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-receives-european-patent-allowance-for-licensed-novel-ptsd-prevention-therapy\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY4NDc0OSM3NTIxNTM3IzUwMDA2OTMzOQ==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-receives-european-patent-allowance-for-licensed-novel-ptsd-prevention-therapy\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-receives-european-patent-allowance-for-licensed-novel-ptsd-prevention-therapy\\\/\",\"name\":\"Silo Pharma Receives European Patent Allowance for Licensed Novel PTSD Prevention Therapy - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-receives-european-patent-allowance-for-licensed-novel-ptsd-prevention-therapy\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-receives-european-patent-allowance-for-licensed-novel-ptsd-prevention-therapy\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY4NDc0OSM3NTIxNTM3IzUwMDA2OTMzOQ==\",\"datePublished\":\"2026-04-06T22:20:37+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-receives-european-patent-allowance-for-licensed-novel-ptsd-prevention-therapy\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-receives-european-patent-allowance-for-licensed-novel-ptsd-prevention-therapy\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-receives-european-patent-allowance-for-licensed-novel-ptsd-prevention-therapy\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY4NDc0OSM3NTIxNTM3IzUwMDA2OTMzOQ==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY4NDc0OSM3NTIxNTM3IzUwMDA2OTMzOQ==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-receives-european-patent-allowance-for-licensed-novel-ptsd-prevention-therapy\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Silo Pharma Receives European Patent Allowance for Licensed Novel PTSD Prevention Therapy\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Silo Pharma Receives European Patent Allowance for Licensed Novel PTSD Prevention Therapy - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-receives-european-patent-allowance-for-licensed-novel-ptsd-prevention-therapy\/","og_locale":"en_US","og_type":"article","og_title":"Silo Pharma Receives European Patent Allowance for Licensed Novel PTSD Prevention Therapy - Market Newsdesk","og_description":"EPO Greenlights Claims Covering Preventative use of therapy targeting 5-HT4 Pathway and Expands Silo Pharma IP Portfolio SARASOTA, FL, April 06, 2026 (GLOBE NEWSWIRE) &#8212; Silo Pharma, Inc. (Nasdaq: SILO) (\u201cSilo\u201d or the \u201cCompany\u201d), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced that the European Patent Office (EPO) has issued a Rule 71(3) communication indicating its intent to grant a patent for an European patent application titled\u00a0\u201cProphylactic Efficacy of Serotonin 4 Receptor Agonists Against Stress\u201d (European Patent Application No. 20786878.7) that the Company has an exclusive license from Columbia University. The allowed claims cover methods of preventing stress-induced fear and depressive-like behavior and associated affective disorders &hellip; Continue reading \"Silo Pharma Receives European Patent Allowance for Licensed Novel PTSD Prevention Therapy\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-receives-european-patent-allowance-for-licensed-novel-ptsd-prevention-therapy\/","og_site_name":"Market Newsdesk","article_published_time":"2026-04-06T22:20:37+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4NDc0OSM3NTIxNTM3IzUwMDA2OTMzOQ==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-receives-european-patent-allowance-for-licensed-novel-ptsd-prevention-therapy\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-receives-european-patent-allowance-for-licensed-novel-ptsd-prevention-therapy\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Silo Pharma Receives European Patent Allowance for Licensed Novel PTSD Prevention Therapy","datePublished":"2026-04-06T22:20:37+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-receives-european-patent-allowance-for-licensed-novel-ptsd-prevention-therapy\/"},"wordCount":554,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-receives-european-patent-allowance-for-licensed-novel-ptsd-prevention-therapy\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4NDc0OSM3NTIxNTM3IzUwMDA2OTMzOQ==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-receives-european-patent-allowance-for-licensed-novel-ptsd-prevention-therapy\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-receives-european-patent-allowance-for-licensed-novel-ptsd-prevention-therapy\/","name":"Silo Pharma Receives European Patent Allowance for Licensed Novel PTSD Prevention Therapy - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-receives-european-patent-allowance-for-licensed-novel-ptsd-prevention-therapy\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-receives-european-patent-allowance-for-licensed-novel-ptsd-prevention-therapy\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4NDc0OSM3NTIxNTM3IzUwMDA2OTMzOQ==","datePublished":"2026-04-06T22:20:37+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-receives-european-patent-allowance-for-licensed-novel-ptsd-prevention-therapy\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-receives-european-patent-allowance-for-licensed-novel-ptsd-prevention-therapy\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-receives-european-patent-allowance-for-licensed-novel-ptsd-prevention-therapy\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4NDc0OSM3NTIxNTM3IzUwMDA2OTMzOQ==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4NDc0OSM3NTIxNTM3IzUwMDA2OTMzOQ=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-receives-european-patent-allowance-for-licensed-novel-ptsd-prevention-therapy\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Silo Pharma Receives European Patent Allowance for Licensed Novel PTSD Prevention Therapy"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/949274","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=949274"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/949274\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=949274"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=949274"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=949274"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}